Cardiotoxicity in oncology and coronary microcirculation: future challenges in theranostics

G Peretto, D Lazzeroni, CL Sartorio, PG Camici

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation. Nowadays many diagnostic and therapeutic options are available both in coronary microvascular dysfunction and cardio-oncology. Aim of this review is to suggest future theranostic implications of the relationship between cardiotoxicity in oncology and coronary microvascular dysfunction, showing common pathophysiologic mechanisms, proposing new diagnostic approaches and therapeutic options for cardioprotection.
Original languageEnglish
Pages (from-to)1760-1773
Number of pages14
JournalFrontiers in bioscience (Landmark edition)
Volume22
Issue number3/4
DOIs
Publication statusPublished - 2017

Fingerprint

Microcirculation
Oncology
Toxicity
Blood Vessels
Angiography
Chemotherapy
Radiotherapy
Complex networks
Coronary Angiography
Muscle Cells
Myocardial Ischemia
Coronary Artery Disease
Neoplasms
Cardiovascular Diseases
Therapeutics
Heart Failure
Drug Therapy
Theranostic Nanomedicine
Cardiotoxicity

Cite this

Cardiotoxicity in oncology and coronary microcirculation: future challenges in theranostics. / Peretto, G; Lazzeroni, D; Sartorio, CL; Camici, PG.

In: Frontiers in bioscience (Landmark edition), Vol. 22, No. 3/4, 2017, p. 1760-1773.

Research output: Contribution to journalArticle

@article{748ba706ba514b52921b6410acd0e68d,
title = "Cardiotoxicity in oncology and coronary microcirculation: future challenges in theranostics",
abstract = "Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation. Nowadays many diagnostic and therapeutic options are available both in coronary microvascular dysfunction and cardio-oncology. Aim of this review is to suggest future theranostic implications of the relationship between cardiotoxicity in oncology and coronary microvascular dysfunction, showing common pathophysiologic mechanisms, proposing new diagnostic approaches and therapeutic options for cardioprotection.",
author = "G Peretto and D Lazzeroni and CL Sartorio and PG Camici",
year = "2017",
doi = "10.2741/4570",
language = "English",
volume = "22",
pages = "1760--1773",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "3/4",

}

TY - JOUR

T1 - Cardiotoxicity in oncology and coronary microcirculation: future challenges in theranostics

AU - Peretto, G

AU - Lazzeroni, D

AU - Sartorio, CL

AU - Camici, PG

PY - 2017

Y1 - 2017

N2 - Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation. Nowadays many diagnostic and therapeutic options are available both in coronary microvascular dysfunction and cardio-oncology. Aim of this review is to suggest future theranostic implications of the relationship between cardiotoxicity in oncology and coronary microvascular dysfunction, showing common pathophysiologic mechanisms, proposing new diagnostic approaches and therapeutic options for cardioprotection.

AB - Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation. Nowadays many diagnostic and therapeutic options are available both in coronary microvascular dysfunction and cardio-oncology. Aim of this review is to suggest future theranostic implications of the relationship between cardiotoxicity in oncology and coronary microvascular dysfunction, showing common pathophysiologic mechanisms, proposing new diagnostic approaches and therapeutic options for cardioprotection.

U2 - 10.2741/4570

DO - 10.2741/4570

M3 - Article

VL - 22

SP - 1760

EP - 1773

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 3/4

ER -